32 unchanged sentences
As a result of these factors, management cannot be certain that the Company will be able to compete against current or future competitors or that competitive pressure will not seriously harm our business.
−Removed: Any failure in protecting our intellectual property may have a negative impact adverse effect on our ability to develop and license DehydraTECH.
+Added: Any failure in protecting our intellectual property may have a negative impact on our ability to develop and license DehydraTECH.
Because patents involve complex legal and factual questions, the issuance, scope, validity, and enforceability of patents cannot be predicted with certainty.
51 unchanged sentences
If any of these terminate, we may be unable to enter into arrangements with alternative providers or to do so on commercially reasonable terms.
−Removed: Switching or adding additional third parties involve increased management time, focus, regulatory approvals and/or additional cost.
+Added: Switching or adding additional third parties involves increased management time, focus, regulatory approvals and/or additional cost.
Any delays in our manufacturing capabilities or research studies may have a material adverse impact on our business, financial condition and prospects.
16 unchanged sentences
Risks Associated with our Financial Condition
+Added: There is substantial doubt as to our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail or cease our operations.
+Added: Our consolidated financial statements as of August 31, 2025 were prepared under the assumption that we will continue as a going concern.
+Added: As of August 31, 2025, we had unrestricted cash and cash equivalents of approximately $1.8 million to settle $1.5 million in current liabilities.
+Added: Our ability to continue as a going concern will depend on our ability to obtain additional equity, effect a collaborative or strategic partnership, reduce or contain expenditures, and, ultimately, to generate revenue.
+Added: Based on these factors, management determined that there is substantial doubt as to our ability to continue as a going concern.
+Added: If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or part of their investment.
+Added: If we seek additional financing to fund our business activities as a result of the substantial doubt as to our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all.
Without additional financing to develop our business plan, our business may fail.
7 unchanged sentences
As a result, we may experience material fluctuations in future operating results on a quarterly and annual basis which could materially affect our business, financial condition, and operating results.
−Removed: The R&D programs required to evidence that DehydraTECH’s demonstrated efficacy also works with other APIs and molecules to develop the evidence may ultimately be unsuccessful.
−Removed: We cannot be certain that our overall business model within any particular sector will ever come to fruition, and if they do, may not generate meaningful profits.
+Added: The R&D programs required to develop the evidence that DehydraTECH’s demonstrated efficacy also works with other APIs and molecules may ultimately be unsuccessful.
+Added: We cannot be certain that our overall business model within any particular sector will ever come to fruition, and even if they do, will generate meaningful profits.
We may not recover all or any portion of our capital investment in our research and technology development, marketing, or other aspects of the business.
30 unchanged sentences
We cannot be certain of the outcome of preclinical testing and clinical studies and results from these studies may not predict the results that will be obtained in later phase trials of our product candidates.
−Removed: Even if we are able to complete our preclinical studies and planned clinical trials in line with our projected timelines, results from such studies and trials may be not replicated in subsequent preclinical studies or clinical trial results.
+Added: Even if we are able to complete our preclinical studies and planned clinical trials in line with our projected timelines, results from such studies and trials may not be replicated in subsequent preclinical studies or clinical trial results.
Additionally, such studies may be delayed due to events beyond our control.
16 unchanged sentences
if granted, approval may be withdrawn or limited if problems with DehydraTECH enhanced formulations emerge or are suggested by the data arising from their use or if there is a change in law or regulation.
−Removed: Any success achieved at a given stage of the clinical trials does not guarantee that the future achievement of success at any subsequent stage, including without limitation, final FDA approval.
+Added: Any success achieved at a given stage of the clinical trials does not guarantee that the future achievement of success at any subsequent stage, including without limitation, final FDA or comparable regulatory authority approval.
Delays or rejections in the regulatory approval process because of additional government regulation resulting from future legislation or administrative action, or from changes in the policies of the FDA or other regulatory bodies during the period of product development, clinical trials, or regulatory review may occur.
6 unchanged sentences
Regulatory approval also requires the submission about the product manufacturing process and the inspection of the manufacturing facilities.
−Removed: Our success is dependent on our or a third parties’ ability to successfully navigate the risks and obstacles associated with obtaining FDA clearance for any DehydraTECH enhanced formulated product.
−Removed: Pharmaceutical products using DehydraTECH with CBD as an API have never been approved for the treatment of any disease.
+Added: Our success is dependent on our or a third parties’ ability to successfully navigate the risks and obstacles associated with obtaining FDA or other regulatory clearance for any DehydraTECH enhanced formulated product.
+Added: Pharmaceutical products using CBD as an API have limited approval for the treatment of any disease.
To date the FDA has approved only limited use of cannabinoids for the treatment of any disease or condition.
The FDA has approved one cannabinoid-derived drug product for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome and three synthetic cannabinoid-related drug products for the treatment of nausea and vomiting caused by cancer chemotherapy.
−Removed: While we expect any product candidates that we develop will be regulated as a new drug under the Federal Food, Drug, and Cosmetic Act, the FDA could decide to regulate them or any other products incorporating DehydraTECH under a different regulatory regime.
+Added: While we expect any product candidates that we develop will be regulated as a new drug under the Federal Food, Drug, and Cosmetic Act, the FDA could decide to regulate them or any other products incorporating DehydraTECH-CBD under a different regulatory regime.
The lack of policies, practices or guidelines may hinder or slow review by the FDA of any regulatory filings that we may submit.
36 unchanged sentences
Our internal controls over financial reporting will not receive the level of review provided by the process relating to the auditor attestation included in annual reports of issuers that are subject to these requirements.
−Removed: We cannot predict if investors will find our common shares less attractive because we are not required to comply with more robust disclosure or the auditor attestation requirements.
+Added: We cannot predict if investors will find our common shares less attractive because we are not required to comply with more robust disclosure or the auditor’s attestation requirements.
If investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and trading prices may be negatively affected.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.